| scholarly article | Q13442814 |
| P2093 | author name string | Wei Wang | |
| Jun Xu | |||
| Chen He | |||
| Huanhuan Zhang | |||
| Baodan Yu | |||
| Chengzhi Zhou | |||
| Jianli Tang | |||
| Junli Wang | |||
| Qiasheng Li | |||
| Runhui Zheng | |||
| Zhiping Fu | |||
| P2860 | cites work | Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer | Q21089654 |
| Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy | Q26798404 | ||
| NK cells and exercise: implications for cancer immunotherapy and survivorship | Q26801757 | ||
| FOXP3+ regulatory T cells in the human immune system | Q29307487 | ||
| Leading Causes of Cancer Mortality - Caribbean Region, 2003-2013. | Q29353589 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| NK cell recognition | Q29615107 | ||
| Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction | Q30583272 | ||
| Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. | Q31118586 | ||
| NKG2D CARs as cell therapy for cancer | Q33595873 | ||
| The Treg/Th17 paradigm in lung cancer | Q33608606 | ||
| Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity | Q34016504 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. | Q34441115 | ||
| Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. | Q34504134 | ||
| Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity | Q34505678 | ||
| Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors | Q34635795 | ||
| Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity | Q34984596 | ||
| Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. | Q35215350 | ||
| NK cell-based immunotherapies in Pediatric Oncology. | Q35600975 | ||
| Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. | Q36403529 | ||
| Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging | Q36414279 | ||
| Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients | Q36498459 | ||
| Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection. | Q36566943 | ||
| CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients | Q36937124 | ||
| Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma | Q37175625 | ||
| Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. | Q37276644 | ||
| FKBP51 increases the tumour-promoter potential of TGF-beta | Q37531822 | ||
| Regulatory T cells in tumor immunity | Q37762224 | ||
| Human CD4+CD25highCD127low/neg Regulatory T Cells | Q37953233 | ||
| Investigation of NK cell function and their modulation in different malignancies. | Q37996368 | ||
| Chemotherapeutic targeting of cancer-induced immunosuppressive cells | Q38207980 | ||
| NK cells regulating T cell responses: mechanisms and outcome | Q38272441 | ||
| FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. | Q38327236 | ||
| Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities. | Q38509534 | ||
| Cancer treatment and survivorship statistics, 2016. | Q38859236 | ||
| Tumor-derived CD4+CD25+ Tregs inhibit the maturation and antigen-presenting function of dendritic cells | Q38889674 | ||
| Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells | Q39254820 | ||
| Increased frequency and suppressive activity of CD127low/− regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement | Q39390853 | ||
| Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. | Q39705105 | ||
| S-1 plus CIK as second-line treatment for advanced pancreatic cancer | Q40231668 | ||
| Human Tumor Antigens and Cancer Immunotherapy | Q41533232 | ||
| Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors | Q41611120 | ||
| T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease | Q41888065 | ||
| New strategies for cancer immunotherapy: targeting regulatory T cells | Q42327237 | ||
| Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3 | Q43435560 | ||
| CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood | Q44786390 | ||
| OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy | Q44805706 | ||
| Protective effect of CD4(+)CD25(high)CD127(low) regulatory T cells in renal ischemia-reperfusion injury. | Q45995528 | ||
| IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. | Q46045080 | ||
| Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer | Q46056802 | ||
| Age and gender leucocytes variances and references values generated using the standardized ONE-Study protocol | Q48818805 | ||
| Palliative thoracic radiotherapy for patients with advanced non-small cell lung cancer and poor performance status | Q53668370 | ||
| Mechanisms of suppression of regulatory T-cells (Treg) | Q54535903 | ||
| [Role of RRM1 in the Treatment and Prognosis of Advanced Non-small Cell Lung Cancer]. | Q55427825 | ||
| Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer | Q56101218 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry | Q77839277 | ||
| [Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma] | Q82726070 | ||
| Clinical study on cytokine induced killer cells therapy to laryngeal cancer after radiotherapy | Q83802809 | ||
| Implication of TGF- as a survival factor during tumour development | Q83975125 | ||
| Regulatory T cells in cancer | Q84073243 | ||
| Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer | Q86687244 | ||
| Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy | Q86865260 | ||
| Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study | Q86938912 | ||
| Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up | Q87620046 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 831-840 | |
| P577 | publication date | 2017-06-08 | |
| P1433 | published in | Experimental and Therapeutic Medicine | Q23979083 |
| P1476 | title | Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer | |
| P478 | volume | 14 |
| Q64058805 | Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro |
| Q64948218 | The expression level of CSDAP1 in lung cancer and its clinical significance. |
| Q58746739 | Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy |
Search more.